WallStSmart

Merck & Company Inc (MRK)vsTwist Bioscience Corp (TWST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 15961% more annual revenue ($65.77B vs $409.48M). MRK leads profitability with a 13.6% profit margin vs -19.9%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

TWST

Avoid

26

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.7Quality: 6.5
Piotroski: 4/9Altman Z: -0.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$119.60

$38.64 premium

UndervaluedFair: $80.96Overvalued
TWSTUndervalued (+58.3%)

Margin of Safety

+58.3%

Fair Value

$119.02

Current Price

$85.17

$33.85 discount

UndervaluedFair: $119.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

TWST2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
19.3%8/10

19.3% revenue growth

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TWST4 concerns · Avg: 3.0/10
Price/BookValuation
11.6x4/10

Trading at 11.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-17.9%2/10

ROE of -17.9% — below average capital efficiency

Free Cash FlowQuality
$-25.55M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : TWST

The strongest argument for TWST centers on Debt/Equity, Revenue Growth. Revenue growth of 19.3% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : TWST

The primary concerns for TWST are Price/Book, EPS Growth, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while TWST is a growth play — different risk/reward profiles.

TWST carries more volatility with a beta of 2.21 — expect wider price swings.

TWST is growing revenue faster at 19.3% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 26/100). TWST offers better value entry with a 58.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Twist Bioscience Corp

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.

Want to dig deeper into these stocks?